PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
2.36
0.5–0.75x TRVN's 3.55. Martin Whitman would question if short-term obligations are sufficiently covered.
2.36
0.5–0.75x TRVN's 3.55. Martin Whitman might be concerned about coverage if a crisis hits.
2.26
Cash Ratio 1.25–1.5x TRVN's 1.88. Bruce Berkowitz might see a strong liquidity buffer compared to the competitor.
-36.71
Both companies show negative interest coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
-17.20
Both companies show negative short-term coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.